Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

Share this content:
Bladder cancer is the sixth most commonly diagnosed cancer in the United States.
Bladder cancer is the sixth most commonly diagnosed cancer in the United States.

The simple extra step of flushing out the bladder with a chemotherapy drug after the removal of a tumor significantly decreased the chances of cancer returning. This finding has been well documented and implemented in Canadian and European clinical trials, but has only recently been conducted on a US population. The result of the phase 3, blinded clinical trial was presented at the 2017 American Urological Association (AUA) Annual Meeting.

Bladder cancer is the sixth most commonly diagnosed cancer in the United States with approximately half of new diagnoses classified as low-grade non-muscle bladder cancer. Treatment involves the removal of cancerous tissue from the bladder, a procedure known as transurethral resection for bladder tumor (TURBT).

In the study 406 patients with non-muscle invading bladder cancer were randomly divided into 2 groups. The treatment group received a single dose infusion of 3.5 ounces of gemcitabine, a common chemotherapy drug, after surgery. Gemcitabine was held in the bladder for 1 hour. The second group received only a saline infusion after surgery. Both groups were monitored for 4 years.

There was a 34% reduction in the reoccurrence of cancer in the patients who received the gemcitabine infusion. These patients also reported more moderate postsurgical pain, but they were less likely than the patients who received the saline infusion to experience other side effects such as bleeding.

"The big deal here is that cancer recurrence is common for people diagnosed with this less aggressive form of bladder cancer," said Edward Messing, an investigator with SWOG, the international clinical trials network funded by the National Cancer Institute, Winfield W. Scott Professor and Chairman of Urology at the University of Rochester, and study presenter. "I know some patients who undergo 4 TURBT procedures a year. If we can cut down on these recurrences, we will save a lot of people a lot of pain, money, and time lost to recovery."


1. Messing E, Tangen C, Lerner S, et al. A phase III blinded study of immediate post-TURBT instillation of gemcitabine verses saline in patients with newly diagnosed or occasionally recurring grade I/II non-muscles invasive bladder cancer: SWOG S0337. Oral presentation at: American Urological Association Annual Meeting 2017; May 12-16, 2017; Boston, MA. Abstract PNFLBA-10.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs